Al B. Benson

Northwestern University — United States

Medicine · Health Sciences

132h-index72.2kcitations811works9.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(259), Gastric Cancer Management and Outcomes(154), Pancreatic and Hepatic Oncology Research(115), Colorectal Cancer Surgical Treatments(97), Hepatocellular Carcinoma Treatment and Prognosis(95)

Publications809 total

Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201
The Oncologist·2025Open Access
Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal Adenocarcinoma
UNC Libraries·2025Open Access
Table 2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Table 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025· 1 citedOpen Access
Supplementary Table S2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Table 3 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Data from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Supplementary Table S4 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Figure 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Supplementary Table S1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Supplementary Table S3 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Supplementary Table S5 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Figure 2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Table 4 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
2025Open Access
Phase II Study of Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and Fluorouracil in Locally Advanced Pancreatic Carcinoma: BTCRC-GI15-067
JCO oncology advances.·2025Open Access
A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
Cancer Research Communications·2025Open Access
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network·2025· 7 cited
Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal Adenocarcinoma
JCO Precision Oncology·2025Open Access
Protected Time, Resources, and Expectations for Academic Oncology Clinical Research Physicians
Journal of the National Comprehensive Cancer Network·2025· 1 cited
Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 2: Appendiceal Tumors with Peritoneal Involvement
Annals of Surgical Oncology·2025
page 1 of 41Next →

Frequent Co-authors

Alan P. Venook(12), Mary F. Mulcahy(10), Leonard B. Saltz(9), Dustin A. Deming(8), Jeffrey A. Meyerhardt(8), Christopher G. Willett(8), Mahmoud M. Al-Hawary(7), John M. Skibber(7), Riad Salem(6), Harry S. Cooper(6), Jean L. Grem(6), Sarah E. Hoffe(6), Steven R. Hunt(6), Natalie Kirilcuk(6), Smitha Krishnamurthi(6), Wells A. Messersmith(6), Steven Nurkin(6), David Shibata(6), Constantinos T. Sofocleous(6), Eden Stotsky‐Himelfarb(6)